Chinese Company Under Congressional Scrutiny Makes Key U.S. Drugs

Source

Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is deeply involved in development and manufacturing of crucial therapies for cancer, cystic fibrosis, H.I.V. and other illnesses.

Chinese Company Under Congressional Scrutiny Makes Key U.S. Drugs

Latest:

US bill to restrict WuXi AppTec, Chinese biotechs revised to give more time to cut ties

Digital Health Pass: IBM and Moderna Hook Up to Capitalize on COVID Reset

USING WHAT HAVE ALREADY BECOME CLICHÉD INDUSTRY BUZZWORDS LIKE “TRANSPARENCY,” “TRUST,” AND EVEN “PRIVACY,” IBM’S DIGITAL HEALTH PASS MARKETING DESCRIBES THE MASS TRACKING APP AS A “SMART WAY TO RETURN TO SOCIETY” THAT ALLOWS PEOPLE TO “RETURN TO THE ACTIVITIES AND THINGS THEY LOVE.”

Digital Health Pass: IBM and Moderna Hook Up to Capitalize on COVID Reset